HERCULES, Calif.– Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of StarBright Violet 515 (SBV515) Dye, the first of a new range of unique fluorescent nanoparticles, for use in flow cytometry. StarBright Dyes are conjugated to a growing range of antibodies and are compatible with most flow cytometers and experimental protocols.

The StarBright Violet 515 Dye with an excitation maximum at 401 nanometer and emission maximum of 516 nanometer offers researchers improved brightness to resolve rare and low antigen density populations more easily. It has a narrow emission profile to reduce spillover into neighboring filters and minimal excitation by other lasers, making it suitable for inclusion in multicolor panels.

The dye is not susceptible to photobleaching, delivers high lot-to-lot reproducibility, and is stable at 4°C with no loss of signal to help ensure consistent staining and deliver reliable results. It has been tested in many common staining buffers and there is no requirement to use a special staining buffer, permitting easy integration into common experimental protocols without compromising performance. StarBright Violet 515 Dye is compatible with Bio-Rad’s ZE5 Cell Analyzer, S3e Cell Sorter, as well as other cytometers, and it is suitable for both conventional and spectral flow.

“StarBright Violet 515 Dye is brighter than other common dyes that emit at similar wavelengths,” said Mike Blundell, Bio-Rad Product Manager, Life Science Group. “The dye is flexible enough to fit into any flow cytometry panel, allowing researchers to multiplex with ease regardless of flow cytometer and experimental protocol, and it offers a superior alternative for fluorophores that have emission maxima between 500 and 550 nanometers.”

For more information about Bio-Rad’s StarBright Violet 515 Dye, please visit: www.bio-rad-antibodies.com/starbright 

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.